Researchers in Krakow, Poland, are pioneering stem cell therapy using autologous AT-MSC cells to treat degenerative diseases like osteoarthritis.
Stem Cell Therapy Shows Promise for Joint Disease
Scientists in Krakow are investigating the use of stem cells to treat degenerative diseases, including osteoarthritis, which affects not only seniors but also active individuals and athletes. This research offers hope for those suffering from painful inflammatory conditions and joint damage.
The team’s approach, termed “a method for maintaining autologous AT-MSC cells,” has been nominated as an innovative “cell-based drug” in the Dziennik Gazety Prawnej’s “Eureka! Discovering Polish Inventions” competition.
Understanding AT-MSC Cells
Professor Ewa Zuba-Surma from the Department of Cell Biology at the Jagiellonian University leads the research team. AT-MSC refers to mesenchymal stem cells isolated from human adipose tissue. “Autologous” means each patient serves as their own donor for therapeutic purposes.
Regenerative Potential of Stem Cells
AT-MSCs are a type of stem cell capable of transforming into various, more mature cell types, including cartilage and bone tissue. These “therapeutic cells” can give rise to osteoblasts and chondrocytes – cells that form cartilage and bone – and possess regenerative functions within these tissues.
Additionally, they secrete factors that promote tissue repair.
Clinical Trial Results Demonstrate Improvement
Research into this therapy is advanced, with the team completing the second phase of clinical trials involving nearly 200 patients with knee osteoarthritis. The AT-MSC stem cells, formulated as an Advanced Therapy Medicinal Product (ATMP), were administered to patients via intra-articular injection.
After six months, researchers observed significant improvements in patients’ quality of life and physical activity, correlated with a reduction in osteoarthritis symptoms, including chronic pain. Professor Zuba-Surma describes this as a “milestone” in patient quality of life.
Future Prospects and Broader Applications
Furthermore, some patients showed improved cartilage structure, indicating the treatment addresses the underlying cause. The team is preparing for phase three clinical trials to facilitate the future commercialization of this “cell-based drug.”
While the initial focus is orthopedics, the potential applications extend beyond. The researchers are exploring the role of extracellular vesicles released by the stem cells – natural “nanocarriers” – which contain substances that can reduce inflammation, enhance blood vessel formation, and protect damaged tissues.